J Ruegemer
Edina, MNNPI 1326007709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,074 of the $95,321 with a category attached, or 89.3%. AstraZeneca accounts for 94.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $66,115 and has fallen 97.2% since, to $1,850 in 2021.
Across 141 payments — averaging $676.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$90K
- Merck$4K
- Sanofi-aventis U.S. LLC$743
- Medtronic$63
- Insulet Corporation$63
- Amgen$54
- plus $165 from 8 others
What the payments were for
- Speaking & faculty fees$85,07489%
- Travel & lodging$7,7458%
- Food & beverage$2,4743%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 106 | $90,465 |
| Merck | 9 | $3,768 |
| Sanofi-aventis U.S. LLC | 2 | $743 |
| Medtronic | 4 | $63 |
| Insulet Corporation | 3 | $63 |
| Amgen | 4 | $54 |
| Dexcom, Inc. | 3 | $37 |
| Companion Medical, Inc. | 3 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Valeritas, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.